Hosted on MSN6h
No Clear Winner in SGLT2 Showdown for Cardiovascular DiseaseTaken at face value, the results would suggest that the three SGLT2 inhibitors are "virtually identical," according to ...
A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback